Somatic Cancer
Liquid Biopsy
SHOP PRODUCTS
The use of blood-based samples to interrogate cancer diseases, i.e., liquid biopsies, has gained importance both as a complementary tool as well as a surrogate sample type to solid tissue biopsies. Seraseq™ circulating tumor DNA (ctDNA) reference materials were developed to support and accelerate the clinical application of liquid biopsy-focused NGS ctDNA assays.
Our patent-pending ctDNA technology enables:
- The most natural cfDNA-like size distribution in the market
- Natural cfDNA-like behavior in library preparation
- Expert-designed constructs with clinically relevant variants
- Highly multiplexed materials
- Broad variant types - SNVs, INDELs, CNVs, and gene fusions
- Better genomic coverage and improved library complexity (molecular diversity)
- Multiple formats - purified ctDNA or full-process in plasma
- Customizable content with the VariantFlex custom platform
Seraseq ctDNA reference materials are purpose-built for ccfDNA-based NGS assay validation and daily run controls and are manufactured in GMP-compliant and ISO 13485-certified facilities.
Appropriate size distribution matters
Our proprietary process produces material with a very narrow size distribution that closely mimics naturally occurring circulating cell-free DNA at both the 170 bp and 340 bp sizes.
 |
Three types of fragmented DNA: random ultrasonicated (green), native cfDNA (orange), and the Seraseq ctDNA Mutation Mix v2 AF 0.5 (blue). Samples were characterized by the Agilent 2100 Bioanalyzer®.
|
Gene List
| AKT1 |
CTNNB1 |
FLT3 |
GNAS |
KRAS |
NRAS/CSDE1 |
RET |
| APC |
EGFR |
FOXL2 |
IDH1 |
MPL |
PDGFRA |
SMAD4 |
| ATM |
ERBB2 |
GNA11 |
JAK2 |
NCOA4-RET |
PIK3CA |
TP53 |
| BRAF |
FGFR3 |
GNAQ |
KIT |
NPM1 |
PTEN |
TPR-ALK |
